Most healthtech decks still assume hospitals have the budget and capacity to care about “efficiency”. They don’t. Talk to real operators, and their priorities are blunt: keep the lights on, pay staff, restock medication, etc. In that world, EMRs and slick workflows are not urgent; reducing the diesel bill or stopping revenue leakage is urgent.

The macro context explains the mood. Per-capita health spending in sub-Saharan Africa is a fraction of global averages, and the region is heading into a severe shortage of clinical staff. Under that pressure, it’s not shocking that “nice” digitisation projects stall. We’ve already seen AI transcription startups abandon hospitals and pivot to call centres, where budgets and ROI are clearer. Meanwhile, tools that cut waste, power-optimisation for clinics, or platforms that help hospitals actually collect revenue get traction quickly because they hit the P&L directly.

By 2026, the healthtech companies that matter will all start with the same question: “Where is money being lost or wasted today, and how do we fix it?” Everything else, structured data, clean interfaces, and improved workflows come after.

During COVID, African healthtech attracted a wave of urgency and donor attention. It was natural to back apps and telemedicine pilots and assume ministries, NGOs or insurers would eventually pay for scale. The reality is more constrained: health budgets are tight everywhere, and out-of-pocket spend across the continent is limited.

The numbers are stark. Healthtech funding in Africa fell about 70% year-on-year in 2024, down to roughly $65m from $212m in 2023, even though around $1bn has been invested in the category since 2019. At the same time, institutions like the African Development Bank committed about $1bn to health projects in 2024, including hospitals and digital tools, delivered through public-private partnerships. The capital has not vanished; it has moved into vehicles that tie innovation directly to reimbursable services in primary care, diagnostics and supply chains.

The founders who will build lasting companies accept that they are selling into governments, donors and insurers first, and only later to consumers, and they design products, pricing and evidence accordingly.